Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (CA2771775) COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS

Office : Canada
Application Number: 2771775 Application Date: 27.08.2010
Publication Number: 2771775 Publication Date: 03.03.2011
Grant Number: Grant Date: 20.01.2015
Publication Kind : C
Prior PCT appl.: Application Number:PCTUS2010046930 ; Publication Number: Click to see the data
IPC:
C07D 403/04
A61K 31/506
A61P 35/00
C07D 401/14
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
403
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506
not condensed and containing further heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14
containing three or more hetero rings
Applicants: IRM LLC
NOVARTIS AG
Inventors:
Priority Data: 61/238,073 28.08.2009 US
61/313,039 11.03.2010 US
Title: (EN) COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
(FR) COMPOSES ET COMPOSITIONS EN TANT QU'INHIBITEURS DE PROTEINE KINASE
Abstract: front page image
(EN) The invention provides a novel class of compounds of formula 1, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.


Also published as:
RSP-2014/0430UAa201203042SG178351IL218084EP2470526DOP2012000051
JP2013503186CN102725283EA201200373EP2727918ES2492499KR1020120062839
TN2012000081NZ598924DK2470526AU2010286569VN30470ID2012/03594
TH140028IN2469/DELNP/2012WO/2011/025927